Eleni Tholouli
Overview
Explore the profile of Eleni Tholouli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
968
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dragoi D, Cusworth S, Oldham L, Sanderson R, Norman J, Chandan J, et al.
Br J Haematol
. 2025 Jan;
PMID: 39821591
Data on the impact of ethnic and socioeconomic factors on Chimeric antigen receptor (CAR) T-cell therapy (access and outcomes are limited, but key to understand whether results from the registration...
2.
Roddie C, Sandhu K, Tholouli E, Logan A, Shaughnessy P, Barba P, et al.
N Engl J Med
. 2024 Nov;
391(23):2219-2230.
PMID: 39602653
Background: Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve persistence. Methods: We conducted...
3.
Lucchini G, Cozma E, Jackson A, Gilmour K, Protheroe R, Wilson K, et al.
Leuk Res
. 2024 Nov;
147:107618.
PMID: 39536686
No abstract available.
4.
Cwynarski K, Iacoboni G, Tholouli E, Menne T, Irvine D, Balasubramaniam N, et al.
Nat Med
. 2024 Nov;
31(1):137-143.
PMID: 39528665
Relapsed/refractory peripheral T cell lymphomas (PTCLs) are aggressive tumors with a poor prognosis. Unlike B cell lymphomas, treatment of PTCL has not benefited from advances in immunotherapy. This is largely...
5.
Mitra R, Tholouli E, Rajai A, Saha A, Mitra S, Mitsides N
J Pers Med
. 2024 Oct;
14(10).
PMID: 39452553
: Acute Kidney Injury (AKI) is a condition that affects a significant proportion of acutely unwell patients and is associated with a high mortality rate. Patients undergoing haemopoietic stem cell...
6.
Arrieta-Bolanos E, Bonneville E, Crivello P, Robin M, Gedde-Dahl T, Salmenniemi U, et al.
J Clin Oncol
. 2024 Aug;
42(28):3287-3299.
PMID: 39167735
PURPOSEHuman leukocyte antigen (HLA) mismatching can reduce survival of patients with blood cancer after hematopoietic cell transplantation (HCT). How recent advances in HCT practice, in particular graft-versus-host disease (GVHD) prophylaxis...
7.
Arrieta-Bolanos E, van der Burg L, Gedde-Dahl T, Robin M, Salmenniemi U, Kroger N, et al.
Blood
. 2024 Aug;
144(16):1747-1751.
PMID: 39102621
HLA-DP permissive mismatches can be assigned a direction according to their immunopeptidome divergence across core and noncore subsets. Noncore permissive graft-versus-host mismatches show significantly reduced risks of relapse without increased...
8.
Spanjaart A, Ljungman P, Tridello G, Schwartz J, Martinez-Cibrian N, Barba P, et al.
Leukemia
. 2024 Jul;
38(9):1985-1991.
PMID: 39043963
COVID-19 has been associated with high mortality in patients treated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome has improved over time...
9.
Montoro J, Eikema D, Tuffnell J, Potter V, Kalwak K, Halkes C, et al.
Blood
. 2024 Apr;
144(3):323-333.
PMID: 38643511
Selecting the most suitable alternative donor becomes challenging in severe aplastic anemia (SAA) when a matched sibling donor (MSD) is unavailable. We compared outcomes in patients with SAA undergoing stem...
10.
Wright P, van de Pasch L, Dignan F, Kichula K, Pollock N, Norman P, et al.
Transplant Cell Ther
. 2024 Feb;
30(5):488.e1-488.e15.
PMID: 38369017
The majority of established KIR clinical assessment algorithms used for donor selection for hematopoietic progenitor cell transplantation (HPCT) evaluate gene content (presence/absence) of the KIR gene complex. In comparison, relatively...